3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Azenosertib: new trials by email Literature Review of Azenosertib trials Research Report on Azenosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma Azenosertib, Gemcitabine - Osteosarcoma | Phase 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 31 | 2021-08-01 | 2026-04-03 |
| A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors Azenosertib - Solid Tumor | Phase 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 274 | 2019-11-01 | 2026-03-18 |
Fallopian Tube Neoplasms (1) · Osteosarcoma (1) · Ovarian Neoplasms (1)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (3)
United States (3) · France (2)